Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
Unemployed -- without a lifeline In July, CNNMoney.com told the stories of 4 out-of-work Americans who had just lost their unemployment benefits. Here's where they are today. Full Article at CNN/Money
-
While global merger and acquisition activity is down by as much as 41% this year according to The Mergermarket Group, don't tell that to lawyers at Cassels, Brock & Blackwell. Full Article at Vancouver Sun
-
Graphic shows 2008 sales for selected Pfizer drugs. View Photo »
-
The leadership contributions from SFU, Pfizer Canada, the Heart and Stroke Foundation and the anonymous donor to St. Paul's Hospital Foundation for this Chair will have a dramatic impact on heart disease prevention at St. Paul's Hospital and SFU, improving the health of people in B.C. and beyond
SOURCE: News-Medical.net -
New Jersey is one of seven states with fuzzy eminent domain laws that make it easier to wrongly take people's property. It's a measure the Garden State should clarify, especially in the wake of the fallout from a landmark Connecticut case. Full Article at Philadelphia Inquirer
-
The lawyers who won $103 million in two jury verdicts announced Monday against Pfizer Inc. relied as much on their storytelling ability as their knowledge of the law. Full Article at Philadelphia Inquirer
-
Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review
News-Medical.net
Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate... Full Article at News-Medical.net
-
Graphic shows 2008 sales for selected Pfizer drugs. View Photo »
-
The approval of Revatio injection is a clear demonstration of Pfizer’s commitment to developing treatments addressing the unmet needs of patients with pulmonary arterial hypertension. This important milestone highlights the Specialty Care business unit’s dedication to advancing treatments for serious an...
SOURCE: Pharmaceutical Business Review -
-
Even with the country’s unemployment rate at its highest in decades, some companies are having trouble hiring highly skilled employees. Full Article at Boston Globe
-
Wyeth and its new parent Pfizer are probably wishing they had more to be thankful for this week, after being hit with jury awards totaling $103 million over hormone drugs. Full Article at Law.com
About Pfizer Inc.
Wikipedia
Pfizer Incorporated (NYSE: PFE) is a pharmaceutical company, ranking number one in sales in the world. The company is based in New York City, with its research headquarters in Groton, Connecticut. Full Article
Related Photos
prev
next
-
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, shake hands at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (R) and Bernard Poussot (L), CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
AP Photo
Jeffrey Kindler, left, chairman and CEO of Pfizer, and Bernard Poussot, president, chairman and CEO of Wyeth, attend a news conference Monday, Jan. 26, 2009 in New York.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
AP Photo
Jeffrey Kindler, chairman and CEO of Pfizer, speaks at a news conference Monday, Jan. 26, 2009 in New York. Pharmaceutical giant Pfizer Inc. is buying rival drugmaker Wyeth in a $68 billion cash-and-stock deal that could reshape the drug development industry.
View Photo » -
AP Photo
Jeffrey Kindler, left, chairman and CEO of Pfizer, and Bernard Poussot, president, chairman and CEO of Wyeth, speak at a news conference Monday, Jan. 26, 2009 in New York.
View Photo » -
AP Photo
Jeffrey Kindler, left, chairman and CEO of Pfizer, and Bernard Poussot, president, chairman and CEO of Wyeth, speak at a news conference Monday, Jan. 26, 2009 in New York.
View Photo » -
AP Photo
Jeffrey Kindler, left, chairman and CEO of Pfizer, and Bernard Poussot, president, chairman and CEO of Wyeth, react to a question at a news conference Monday, Jan. 26, 2009 in New York.
View Photo » -
AP Photo
Jeffrey B. Kindler, chief executive of Pfizer, left, and Bernard Poussot, chief executive of Wyeth, discuss the planned combination of their companies, announced in New York Monday, January 26, 2009.
View Photo » -
AP Photo
Jeffrey B. Kindler, chief executive of Pfizer, left, and Bernard Poussot, chief executive of Wyeth, discuss the planned combination of their companies, announced in New York Monday, January 26, 2009.
View Photo » -
AP Photo
A sign at Pfizer world headquarters is shown Sunday, Jan. 25, 2009 in New York. Pfizer Inc. says its fourth-quarter profit plunged 90 percent on a hefty legal settlement for investigations into the company's marketing practices.
View Photo » -
AP Photo
A sign at Pfizer world headquarters is shown Sunday, Jan. 25, 2009 in New York. It was announced Monday Jan. 26, 2009 that Pfizer Inc. reached an agreement to acquire Wyeth in deal valued at $68 billion. (.
View Photo » -
AP Photo
A sign at Pfizer world headquarters is shown Sunday, Jan. 25, 2009 in New York. It was announced Monday Jan. 26, 2009 that Pfizer Inc. reached an agreement to acquire Wyeth in deal valued at $68 billion.
View Photo » -
AP Photo
Bottle's of Pfizer's Lipitor, left, and Wyeth's Effexor are shown Sunday, Jan. 25, 2009 in New York. It was announced Monday Jan. 27, 2009 that Pfizer Inc. reached an agreement to acquire Wyeth in deal valued at $68 billion.
View Photo » -
Getty Images
NEW YORK - APRIL 17: (FILE PHOTO) Pedestrians walk past the world headquarters of Pfizer Inc. April 17, 2008 in New York City. Pfizer, the world's largest research-based pharmaceutical company, announced January 13, 2009 that they're cutting 800 research jobs.
View Photo » -
AP Photo
Develop Don't Destroy spokesman and lead plaintiff Daniel Goldstein addresses the media in front of Freddy's Bar, one of the businesses affected by the decision of New York's top court that the state can use eminent domain to force homeowners and businesses to sell their properties for...
View Photo » -
Getty Images
LONDON, ENGLAND - NOVEMBER 23: Jeffrey B Kindler, the Chairman and CEO of Pfizer, delivers a speech to the CBI annual conference at the Park Lane Hilton hotel on November 23, 2009 in London, England.
View Photo » -
Getty Images
LONDON, ENGLAND - NOVEMBER 23: Jeffrey B Kindler, the Chairman and CEO of Pfizer, delivers a speech to the CBI annual conference at the Park Lane Hilton hotel on November 23, 2009 in London, England.
View Photo » -
Getty Images
LONDON, ENGLAND - NOVEMBER 23: Jeffrey B Kindler, the Chairman and CEO of Pfizer, delivers a speech to the CBI annual conference at the Park Lane Hilton hotel on November 23, 2009 in London, England.
View Photo » -
Getty Images
LONDON, ENGLAND - NOVEMBER 23: Jeffrey B Kindler, the Chairman and CEO of Pfizer, delivers a speech to the CBI annual conference at the Park Lane Hilton hotel on November 23, 2009 in London, England.
View Photo » -
Getty Images
LONDON, ENGLAND - NOVEMBER 23: Jeffrey B Kindler, the Chairman and CEO of Pfizer, delivers a speech to the CBI annual conference at the Park Lane Hilton hotel on November 23, 2009 in London, England.
View Photo » -
AP Photo
FILE - In this Jan. 25, 2009 file photo, the company logo for drugmaker Pfizer Inc. , is shown. Pfizer Inc. posts a higher third-quarter profit Tuesday, Oct. 20, 2009,despite the recession, as sharp cost cuts make up for slightly lower sales.
View Photo » -
AP Photo
Pfizer and Wyeth companies become one - Pfizer scientists at Grange Castle, Clondalkin, Ireland, one of the world's leading biopharmaceutical campuses. The combined operation is a more diversified health care company with expanded leadership in human, animal and consumer health.
View Photo » -
Getty Images
WASHINGTON - SEPTEMBER 02: Helath and Human Services Secretary Kathleen Sebelius (R) announces that pharmaceutical giant Pfizer will pay a record $2.3 billion settlement for illegal drug promotion with Associate Attorney General Tom Perrilli (L) at the Department of Justice September 2...
View Photo »
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, shake hands at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »Related Topics
Related Videos
Related Quotes
- Previous
- Next
- 1/25
-
While the court understands there may be some delay in producing discovery, Pfizer did not represent to the court that its production would be a long slow rolling production ... In the court's view the record reveals that Pfizer's conduct has not risen to a level of willful and intentional disobedience....
SOURCE: Deseret News -
While the court understands there may be some delay in producing discovery, Pfizer did not represent to the court that its production would be a long slow rolling production ... In the court's view the record reveals that Pfizer's conduct has not risen to a level of willful and intentional disobedience....
SOURCE: Deseret News -
While the court understands there may be some delay in producing discovery, Pfizer did not represent to the court that its production would be a long slow rolling production ... In the court's view the record reveals that Pfizer's conduct has not risen to a level of willful and intentional disobedience....
SOURCE: Deseret News -
Pfizer recognises the value of our sales and marketing network for the sale of its established products in the pharmacy market in Australia
SOURCE: The Age -
Hopefully [the acquisition of Wyeth] will help supplant the loss of Lipitor [Pfizer's wildly successful cholesterol drug] when it goes off-patent in 2011.
SOURCE: Globe and Mail -
AFER is proud to have the opportunity to honor early career researchers for their achievements through the AFER/Pfizer Ophthalmics Translational Research Awards ... We are grateful for Pfizer Ophthalmics' support and commitment to life-changing ophthalmic research.
SOURCE: Medical News Today -
AFER is proud to have the opportunity to honor early career researchers for their achievements through the AFER/Pfizer Ophthalmics Translational Research Awards ... We are grateful for Pfizer Ophthalmics' support and commitment to life-changing ophthalmic research.
SOURCE: Medical News Today -
Like Carl Camras, Pfizer Ophthalmics is dedicated to making a difference in the lives of patients by collaborating with stakeholders to advance the science and care in the field of eye disorders
SOURCE: Medical News Today -
Pfizer approached Mankind Pharma with a lucrative offer, valuing the India company at $1 billion
SOURCE: PharmaTimes -
The main difference is that the combined marketing power of Pfizer products marketers in Israel is boosted by the merger. Together, we're one of the leading marketers in Israel. The important thing for us is that every Pfizer representative in Israel will also represent the company's values.
SOURCE: Globes Online -
The main difference is that the combined marketing power of Pfizer products marketers in Israel is boosted by the merger. Together, we're one of the leading marketers in Israel. The important thing for us is that every Pfizer representative in Israel will also represent the company's values.
SOURCE: Globes Online -
Caliper Life Sciences is a strategic partner of Pfizer Global Research & Development.
SOURCE: Freshnews.com -
We expect these results to represent a tailwind for large pharma today even though Pfizer's numbers may not translate directly to the rest of the group
SOURCE: Philadelphia Inquirer -
The decision is in the hands of the payer organizations now ... Payers will take a close look at the TRITON data when determining Effient's reimbursement status compared to Plavix. The data create a complex decision-making process. This is not as clear-cut as, say, Pfizer's early strategy with Lipitor.
-
We continue to envision a future where animal health care providers, veterinarians and livestock producers look to Pfizer first to help them to run their practice or operation productively and profitably. With our newly expanded portfolio, value-added services and high-caliber talent, Pfizer is more foc...
SOURCE: All American Patriots -
We continue to envision a future where animal health care providers, veterinarians and livestock producers look to Pfizer first to help them to run their practice or operation productively and profitably. With our newly expanded portfolio, value-added services and high-caliber talent, Pfizer is more foc...
SOURCE: All American Patriots -
Pfizer Animal Health is passionate about working hand-in-hand with our customers and partners to transform the care, health and well-being of animals
SOURCE: All American Patriots -
As a long time supporter of United Way and the community, Pfizer is pleased to donate this surplus furniture available to those who will use it as part of their mission to help people in need
SOURCE: Terre Haute News -
Our products, services and expertise will expand what is already a robust U.S. portfolio while enhancing our position in the animal health marketplace. Pfizer Animal Health is dedicated to working alongside our customers and partners to transform the care, health and well-being of animals
SOURCE: Injury Board -
We don't know if the Justice Department is making an example of Pfizer to keep others from engaging in this behavior, but usually it does have that kind of outcome
SOURCE: Shanghai Daily -
Pfizer will benefit greatly from the expertise of the Executive Leadership Team, and the diversity of experience it represents ... Our creation of the Executive Compliance Committee will serve as an important addition to our compliance infrastructure, and ensure the dedicated involvement of our senior-m...
SOURCE: News-Medical.net -
For example, rimonabant, a Sanofi-Aventis drug once viewed a surefire blockbuster, failed to win F.D.A. approval in 2007 because of links to depression and suicidalthoughts. The drug, also known as Acomplia, was then taken off the market in Europe. And Merck and Pfizer abandoned their efforts to develop...
SOURCE: Newsvine -
From today, Pfizer is going to run two highly innovative research divisions
SOURCE: KIVITV.com -
Amgen and Pfizer are committed to ongoing research of ENBREL to grow the overall amount of information available about ENBREL and its safety and efficacy profile.
SOURCE: RedOrbit -
I've seen a great deal of evidence that Pfizer intends to make the new company a newer and better Pfizer, as opposed to the old Pfizer with some additional products
– Germano SOURCE: Philadelphia Inquirer
– Related Conversations
There are no results for this module. Edit the module to change the search term used to query Twitter.